Abstract
BackgroundThe standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [18F]fluorodeoxyglucose (FDG), Km. Among the shortcomings are time dependence, susceptibility to errors in scanner and dose calibration, insufficient correlation between systemic distribution volume and body weight, and, consequentially, residual inter-study variability of the arterial input function (AIF) despite SUV normalization. Especially the latter turns out to be a crucial factor adversely affecting the correlation between SUV and Km and causing inter-study variations of tumor SUVs that do not reflect actual changes of the metabolic uptake rate. In this work, we propose to replace tumor SUV by the tumor-to-blood standard uptake ratio (SUR) in order to distinctly improve the linear correlation with Km.MethodsAssuming irreversible FDG kinetics, SUR can be expected to exhibit a much better linear correlation to Km than SUV. The theoretical derivation for this prediction is given and evaluated in a group of nine patients with liver metastases of colorectal cancer for which 15 fully dynamic investigations were available and Km could thus be derived from conventional Patlak analysis.ResultsFor any fixed time point T at sufficiently late times post injection, the Patlak equation predicts a linear correlation between SUR and Km under the following assumptions: (1) approximate shape invariance (but arbitrary scale) of the AIF across scans/patients and (2) low variability of the apparent distribution volume Vr (the intercept of the Patlak Plot). This prediction - and validity of the underlying assumptions - has been verified in the investigated patient group. Replacing tumor SUVs by SURs does improve the linear correlation of the respective parameter with Km from r = 0.61 to r = 0.98.ConclusionsSUR is an easily measurable parameter that is highly correlated to Km. In this respect, it is clearly superior to SUV. Therefore, SUR should be seriously considered as a drop-in replacement for SUV-based approaches.
Highlights
The standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [18F]fluorodeoxyglucose (FDG), Km
Today, in the clinical oncological setting, the standard uptake value (SUV, g/ml), defined as the tracer concentration at a certain time point normalized to injected dose per unit body weight is essentially the only means for quantitative evaluation of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)
We propose to replace tumor SUVs by the tumor-to-blood uptake ratio, called standard uptake ratio (SUR), in the following: SUR can be expected on theoretical grounds to exhibit a much better linear correlation to Km than SUV
Summary
The standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [18F]fluorodeoxyglucose (FDG), Km. While it is perfectly possible to quantify the targeted parameter, namely the absolute metabolic rate of glucose consumption (or, rather, the rate of irreversible FDG accumulation, Km), the conventional approaches such as the Patlak plot [1,2] require to a varying degree dynamic imaging and determination of the full arterial input function both of which requirements are not compatible with oncological whole body imaging For this reason, different alternative approaches have been investigated in the past which have tried to facilitate the quantification of Km in order to make it more suitable for the oncological setting [3,4,5,6,7,8]. While such dual time point protocols could be considered acceptable for clinical routine, they still do somewhat increase complexity of the work flow and data evaluation and will probably only augment but not replace static oncological imaging
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
